Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.
[Fate Therapeutics, Inc.]
7992332
{7992332:CCCCCCCC}
apa
50
1
170619
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/